ABCL (AbCellera Biologics) Institutional Ownership: 40.70% (As of Jul. 01, 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $7.60
GF Value $5.54
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Institutional Ownership?

AbCellera Biologics ABCL -3.12% 59 Institutional Ownership is 40.70% as of Jul. 01, 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.54 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AbCellera Biologics's institutional ownership is 40.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AbCellera Biologics's Insider Ownership is 1.61%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AbCellera Biologics's Float Percentage Of Total Shares Outstanding is 77.16%.

AbCellera Biologics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Institutional Ownership Chart

AbCellera Biologics Historical Data

The historical data trend for AbCellera Biologics can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 12.30 10.89 11.27 8.71 8.16 8.15 7.75 7.70 7.62 7.63
ABCL
59GF Score
AbCellera Biologics Inc ABCL
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 40.70% mean?
AbCellera Biologics (ABCL) has a Institutional Ownership of 40.70% as of Jul. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AbCellera Biologics and its competitors.
Is AbCellera Biologics' Institutional Ownership too high?
AbCellera Biologics' current Institutional Ownership is 40.70%. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Institutional Ownership compare to AGIO and KOD?
AbCellera Biologics' Institutional Ownership of 40.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Institutional Ownership is 40.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.54, compared to a current price of $7.60 — trading 37.1% above its estimated fair value. The current Institutional Ownership is 40.70%. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Institutional Ownership is 40.70% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.60 is trading 37.1% above its estimated GF Value™ of $5.54. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Institutional Ownership: 40.70%
  • GF Value™: $5.54 vs. price of $7.60 (37.1% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.60
Price
$5.54
GF Value